Memphis Meats has changed its name to Upside Foods as it prepares to bring its cell-cultured chicken product to market by the end of this year.
The product is pending regulatory approval.
That would likely be the first commercialized lab-grown meat product sold in the U.S.
Cultured chicken is currently being sold in a restaurant in Singapore.
Memphis Meats was a leader in “animal cell culture technology,” producing what is claimed to be the world’s first lab-grown meatball in 2016 and the first lab-grown poultry in 2017.
The company announced the name change to Upside Foods on May 12.
Upside Foods CEO Uma Valeti said their new name showcases the work they are doing to eating meat and that they can't wait for consumers to try our Upside chicken soon.


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



